# GLP-1 side effects in the first weeks

Nausea and bowel changes are common with semaglutide and tirzepatide. Severity, persistence and warning symptoms determine what needs attention.

Canonical: https://velri.co/blog/glp-1-side-effects-first-weeks-what-to-expect
Publisher: Velri (https://velri.co/about)
Published: 2026-06-14
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Nausea, vomiting, diarrhea and constipation are common side effects of approved semaglutide and tirzepatide weight-management products. Early follow-up is about how those symptoms affect eating, drinking and daily life, as well as whether treatment is helping. [1][2]

## Why the early weeks can feel different

Both medicines affect appetite and delay stomach emptying. Gastrointestinal symptoms were frequently reported during treatment escalation in clinical trials; the tirzepatide label notes that most nausea, vomiting and diarrhea events occurred during that period and decreased over time. [1][2]

Persistent symptoms need review, particularly when they interfere with eating or drinking. [1][2]

## What makes a symptom important?

Its effect matters as much as its name. Occasional nausea and repeated vomiting that prevents fluid intake are different situations. The labels warn that gastrointestinal fluid loss can lead to dehydration and acute kidney injury, particularly around starting treatment or increasing it. [1][2]

A useful symptom description includes when it started, how often it occurs, whether food or fluids stay down, bowel changes and the prescribed product. This gives the clinician a clearer picture of tolerability.

## Symptoms that should not wait

Persistent or severe abdominal pain, especially pain that extends to the back, can be a warning sign of pancreatitis and needs prompt medical assessment. Gallbladder problems are another recognized risk in both labels. [1][2]

Confusion, fainting or little to no urination can signal severe dehydration and require immediate medical help. [3]

The plan for early side effects should identify who to contact and how treatment will be reviewed if symptoms interfere with nutrition or hydration. Changing the prescribed schedule is a clinical decision; the important information to supply is what the symptoms are actually doing to your day. [1][2]

## Sources
[1] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[2] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[3] Dehydration: MedlinePlus (2024). https://medlineplus.gov/dehydration.html

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support